Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine ... 
MarketWatch (press release)
The patent includes claims that cover Inovio's synthetic consensus HPV antigens and DNA constructs and vaccines that include these antigens, including Inovio's cervical dysplasia/cancer vaccine, VGX-3100. This patent also covers methods of treating a ...
Inovio Pharma awarded U.S. Patent covering SynCon Vaccine For Cervical Dysplasia RTT News
Inovio granted US patent protection for cervical dysplasia/cancer vaccine Proactive Investors UK
Inovio wins US patent for cervical dysplasia, cancer vaccine Pharmaceutical Business Review

all 28 news articles » 

5 Things You Should Reveal to Your OBGYN 
Huffington Post (blog)
If you have had Human Papilloma Virus or HPV, or a treatment for cervical dysplasia or abnormal cells on your cervix with a procedure called a LEEP. It is important for your OB to know this. Your OB may see you more frequently if you have had an ...

 

Inovio Pharmaceuticals advances universal flu vaccine strategy with avian flu ... 
Proactive Investors UK
The T cell responses from this study "mirrored the best-in-class T cell responses" generated from Inovio's other Phase I SynCon vaccine trials for HIV and cervical cancer/dysplasia, the company said. Inovio is advancing its universal flu vaccine ...
Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective ... MarketWatch (press release)

all 21 news articles » 

Low-dose Contraceptive Patch Works 
dailyRx
According to the researchers, the women experienced side effects that included abnormal changes in cervix cells (cervical dysplasia), common cold (nasopharyngitis), nausea, upper respiratory infection, sinusitis, headache, urinary tract infection, ...

 

Inovio Pharmaceuticals to Present at SPI 2012 
PR Newswire (press release)
Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer ...

and more » 

How you can prevent cervical cancer 
India.Com Health
Studies have related the number of sexual partners to HPV and thus cervical cancer. Quit smoking and avoid second-hand smoke. Research has shown that tobacco smoke combined with HPV infection accelerates the rate of cervical dysplasia.
CIN Special Report: Part I, Can a Dangerous Pre-Cancer Threat Be Tamed? OneMedPlace (blog)
Putting off Pap: Doctors, patients adapt to new guidelines that say women can ... Columbus Dispatch

all 38 news articles » 

Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results 
MarketWatch (press release)
Enrollment is ongoing in Inovio's phase II clinical study of VGX-3100 for cervical dysplasia. Data is expected in the second half of 2013. The company's collaborators, the University of Southampton and ChronTech Pharma AB, continue their enrollment of ...
Inovio says it has "expanding dialog" to secure non-dilutive funding Proactive Investors USA & Canada

all 21 news articles » 

Guided Therapeutics' LuViva(R) Advanced Cervical Scan Combined with HPV ... 
MarketWatch (press release)
Sensitivity is the ability to correctly identify moderate and high-grade dysplasia; negative predictive value is the percentage of subjects with a negative test result who are correctly diagnosed. The poster was authored by Dr. Marc L Winter of the ...

and more » 

BRLI Announces InCellDx Investment and Launch of GenCerv Test Through its ... 
MarketWatch (press release)
"We believe that this test has a high positive predictive value for high grade cervical dysplasia in cervical biopsies. We expect that quantitative HPV E6/E7 testing will provide information that should limit the colposcopies and cervical biopsies ...

and more » 

New Phase III Data Show Agile Therapeutics' Low-Dose Patch Is Comparable to ... 
MarketWatch (press release)
The most common adverse reactions (> 2%) in clinical trials were cervical dysplasia (6.2%), nasopharyngitis (5.7%), nausea (4.4%), upper respiratory infection (3.8%), sinusitis (3.6%), headache (3.6%), urinary tract infection (3.3%), human papilloma ...

and more »